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COST-EFFECTIVENESS ANALYSIS OF
SIMVASTATIN AND LOVASTATIN/EXTENDED-
RELEASE NIACIN TO ACHIEVE LDL AND HDL
GOAL USING NHANES DATA
Armstrong EP, Zachry III WM, Malone DC
University of Arizona,Tucson, AZ, USA
OBJECTIVES: The purpose of this study was to investi-
gate the likelihood of achieving both LDL and HDL goals
in the primary prevention of cardiovascular disease using
an epidemiologic sample of United States residents by
comparing simvastatin to a combined regimen of lovas-
tatin/extended-release niacin. An additional objective was
to estimate the cost-effectiveness of each product and the
incremental cost-effectiveness ratio between regimens.
METHODS: A decision analytic model was developed to
compare the cost-effectiveness of simvastatin and lovas-
tatin/extended-release niacin. Product labeling estimated
the change in cholesterol concentrations and the fre-
quency of clinically important adverse events. The Third
National Health and Nutrition Examination Survey
(NHANES) adult data were used to estimate population
cholesterol levels. Average wholesale price was used for
medication costs. RESULTS: The NHANES data revealed
there were 256 patients (10.5%) that required a LDL goal
of <160mg/dL, 1268 (52.2%) that required a goal of
<130mg/dL, and 906 patients (37.3%) that required a
goal of <100mg/dL. For both the 130mg/dL and 100
mg/dL LDL goal analyses (and HDL ≥40mg/dL), lovas-
tatin/extended-release niacin had higher success rates and
lower average total costs than simvastatin. Simvastatin
had the highest success rate in achieving LDL level 
<160mg/dL and HDL ≥40mg/dL. However, the average
total health system cost (medications, physician visit
costs, and laboratory costs) to use simvastatin was
approximately twice that of lovastatin/extended-release
niacin ($665 versus $332). CONCLUSIONS: For LDL
goals <130 and <100mg/dL (and HDL ≥40mg/dL), lovas-
tatin/ extended-release niacin was both more successful
and less costly than simvastatin.
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OBJECTIVES: To quantify the major determinants of
population cost effectiveness of clinical guidelines for risk
screening and prevention of cardiovascular disease (CVD)
with “statin” therapy. METHODS: Risk proﬁles were
collected for 4704 men age 35–84y and 1216 women age
45–84y without CVD. 5-year risk of a cardiovascular
hospital admission for each individual was calculated
using a Framingham risk equation. The predicted number
of incident events in 5 years was scaled by age and gender
to the 2001 NZ census population and integrated over
age groups. Costs, beneﬁts and cost effectiveness were
estimated at treatment thresholds Tc/HDLc = 4.0 to 6.5
and 5y risk 10% or 15%; and screening age thresholds
35/45 (M/F) to 50/60y and treatment adherence 50% to
84%. RESULTS: In the NZ population of 784K men age
35–84y and 558K women age 45–84y, at treatment
thresholds of Tc/HDLc = 5.5 and 15% 5y risk, 56K men
and 20K women would be eligible for prophylaxis. 
Compared to no intervention, 5y prophylaxis with 84%
adherence would avert 3875 incident cardiovascular
events and add 3712 life years at an incremental cost of
$NZ29M and ICER < $NZ8000 ($US4000) per event
avoided or LYG (discounted at 5%). The ICERs change
2 to 3-fold with treatment adherence (50% vs 84%),
threshold lipid ratio (4.5 or 6.5 vs 5.5) and threshold
screening age (50/60 vs 35/45) but less than 25% with
treatment efﬁcacy (24% vs 30%) and the 5y risk treat-
ment threshold (10% vs 15%). The cost per LYG also
depends strongly on the 5y cardiovascular fatality rate
and the discount rate. CONCLUSIONS: Prophylaxis
with ‘statins’ is very cost effective at current drug prices
and clinically realistic treatment thresholds. Clinical
guidelines for cardiovascular prophylaxis should focus on
the threshold age for risk screening, the threshold lipid
ratio and methods for enhancing treatment adherence.
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COST EFFECTIVENESS ANALYSIS OF HMG-COA
REDUCTASE INHIBITORS IN A MEDICAID
POPULATION
MacLean EA, Mofﬁtt CM
Pﬁzer, Inc, Wakeﬁeld, RI, USA
OBJECTIVES: This retrospective analysis of publicly
available pharmacy claims data evaluates prescription
trends and estimates cost effectiveness of statins based 
on acquisition cost and LDL-C lowering capacity.
METHODS: Massachusetts Medicaid statin utilization
data for 2001 was obtained from the Centers for
Medicare and Medicaid (CMS) website (www.cms.gov/
medicaid/drugs/drug5.htm). Units per prescription,
average cost per prescription, marketshare, days supply,
and average cost per day were calculated. The annual cost
per percent LDL-C reduction was calculated by dividing
the annual cost by the percent LDL lowering capacity.
These methods modeled the CURVES study and a subse-
quent pharmacoeconomic analysis by Hilleman, et al.
LDL-C lowering capacity was obtained from the package
insert for drug strengths not studied in the CURVES
study. Drugs were compared based on equipotent LDL-C
lowering capacity. Acquisition costs were not reﬂective of
manufacturer rebates. RESULTS: The statin market was
comprised of atorvastatin at 67.33%, simvastatin at
14.76%, pravastatin at 10.74%, lovastatin at 3.91% and
ﬂuvastatin at 3.25%. Atorvastatin 10mg, the most com-
monly prescribed agent (40.02%), was the most cost
effective agent with an annual patient cost per percent
